Results 11 to 20 of about 7,787 (204)
PLoS Neglected Tropical Diseases, 2015 BackgroundChagas disease is an anthropozoonosis caused by Trypanosoma cruzi. Two drugs are currently used for the etiological treatment of the disease: Nifurtimox (Lampit) and Benznidazole.
Felipe Guhl, Juan D Ramírez
exaly +3 more sources
Enantioselective Properties of Neglected Drug Nifurtimox on Polysaccharide and Macrocyclic Glycopeptide Chiral Stationary Phases by Green HPLC Separation Methods. [PDF]
J Sep SciABSTRACT Nifurtimox (NFX) is a chiral drug used for the treatment of Chagas Disease. Little attention has been paid to the enantioselective properties of chiral drugs used for neglected tropical diseases, highlighting the need for further studies in this area.
Mohr A +4 more
europepmc +2 more sources
Cutaneous reactions during treatment with Nifurtimox or Benznidazole among Trypanosoma cruzi seropositive adults without symptomatic cardiomyopathy: A safety sub analysis of a placebo-controlled randomised trial. [PDF]
Trop Med Int HealthAbstract Objectives To determine, in a randomised placebo‐controlled trial, if cutaneous adverse reactions during treatment (CARDT) with Benznidazole occur as often as with Nifurtimox, and whether the dose and duration of treatment change that frequency.
Villar JC +7 more
europepmc +2 more sources
Frontiers in Cellular and Infection Microbiology, 2022 Trypanosoma cruzi is the causative agent of Chagas disease which is currently treated by nifurtimox (NFX) and benznidazole (BZ). Nevertheless, the mechanism of action of NFX is not completely established.
Gabriela Specker +3 more
doaj +1 more source
Continuous Flow Synthesis of Nitrofuran Pharmaceuticals Using Acetyl Nitrate. [PDF]
Angew Chem Int Ed EnglA robust, automated continuous flow system enables safe, high‐yield nitration of furfural to key nitrofuran intermediates using in situ acetyl nitrate generation. Demonstrated on representative essential World Health Organization (WHO) active pharmaceutical ingredients (API), this innovative open‐source platform ensures rapid synthesis, enhanced safety,
Hellwig H +8 more
europepmc +3 more sources
Frontiers in Parasitology, 2023 Determining the success of antitrypanosomal therapy for Chagas disease is challenging, particularly in the chronic phase of the disease, because seropositivity persists for a long time after successful antitrypanosomal treatment and is known to be ...
Ulrike Grossmann, Maria-Luisa Rodriguez
doaj +1 more source
PLoS Neglected Tropical Diseases, 2021 Nifurtimox is indicated in Chagas disease but determining its effectiveness in chronic disease is hindered by the length of time needed to demonstrate negative serological conversion. We manually reviewed long-term follow-up data from hospital records of
David Vizcaya +8 more
doaj +1 more source
Biomédica: revista del Instituto Nacional de Salud, 2020 Introducción. Trypanosoma cruzi, agente causal de la enfermedad de Chagas, exhibe una sustancial heterogeneidad fenotípica y genotípica que puede influir en las variaciones epidemiológicas y clínicas de la enfermedad, así como en la sensibilidad a los ...
Nidia Acosta +6 more
doaj +1 more source
Frontiers in Parasitology, 2023 Chagas disease (CD) caused by Trypanosoma cruzi remains a Neglected Tropical Disease with limited access to diagnosis and treatment, particularly for chronically infected patients.
Alejandro G. Schijman
doaj +1 more source